Articles from Dark Horse Consulting Group

WALNUT CREEK, Calif. and SHANGHAI, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group (DHCG) marked the opening of its Shanghai office with a ribbon cutting ceremony celebrating Dark Horse Consulting China. The event brought together DHCG leadership, “Shanghai Center of Biomedicine Development”, “China leading CDMO and CRO companies”, and invited guests from across the region's life sciences community. Anthony Davies, Ph.D., Founder and CEO, led the ceremony, joined by John Ng, MBA, General Manager, DHC Asia Pacific, and Kang Liu, Ph.D., Senior Director, Head of China. The ribbon cutting ceremony is jointly performed by Mr. Zhang Hua, Deputy Director at Shanghai Center of Biomedicine Development, Anthony Davies, Founder and CEO at DHCG and John Ng, GM APAC at DHCG.

WALNUT CREEK, Calif. and SHANGHAI, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group (DHCG), a leading life sciences consulting firm specializing in advanced therapies, today announced the formation of Dark Horse Consulting China and the appointment of Kang Liu, Ph.D. as its inaugural hire. The new office, located in Shanghai, reflects DHCG’s strategic commitment to helping biotherapeutic developers capitalize on China’s rapidly advancing life sciences ecosystem, including its world-class CDMO and CRO infrastructure, streamlined regulatory pathways to first-in-human (FIH), and growing role as a global hub for clinical data generation.

WALNUT CREEK, Calif. and SUZHOU, China, June 03, 2026 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, and Altruist Biologics, a wholly-owned subsidiary of Innovent Biologics and global contract development and manufacturing organization (CDMO) specializing in the development and cGMP manufacture of biologics, today announced the signing of a Memorandum of Understanding (MOU) to establish a strategic collaboration aimed at accelerating the development and global commercialization of biologic therapies.

WALNUT CREEK, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, and KunTuo Medical Research and Development (Beijing) Co., Ltd. (“KunTuo”), a full-service contract research organization (CRO) dedicated to clinical research services in China, today announced the signing of a Memorandum of Understanding (MOU) to establish a strategic collaboration aimed at providing biotherapeutics developers with a comprehensive, integrated path to conducting clinical trials in China.

WALNUT CREEK, Calif. and SUZHOU, China, April 26, 2026 (GLOBE NEWSWIRE) --

WALNUT CREEK, Calif. and TOKYO, April 21, 2026 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group (“DHCG” or “the Group”) today announced the acquisition of CJ PARTNERS (“CJP”), a distinguished consulting and advisory firm specializing in bridging the gap between Western and Eastern therapeutic developers and stakeholders — including regulators (PMDA), investors, and commercial partners — to reduce entry risk, accelerate development programs, and maximize global development opportunities around the world. CJP, as a Dark Horse Consulting Group company, further expands DHCG’s Asian Pacific foothold.

Walnut Creek, CA; Boston, MA, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group ("DHC"), the leading global consultancy to the cell and gene therapy (“CGT”) industry, and WestView Capital Partners (“WestView”), a Boston-based growth equity firm, are pleased to jointly announce that WestView has completed a growth investment in DHC.

Walnut City, CA; Boston, MA, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group ("DHC"), the leading global consultancy to the cell and gene therapy (“CGT”) industry, and WestView Capital Partners (“WestView”), a Boston-based growth equity firm, are pleased to jointly announce that WestView has completed a growth investment in DHC.